Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

Core Insights - Kronos Bio, Inc. has initiated an expansion cohort for KB-0742, targeting platinum-resistant high-grade serous ovarian cancer (HGSOC) patients with a dosing schedule of 80mg on a four-days-on, three-days-off basis [1][5] - The company plans to provide an efficacy update for this cohort in the first half of 2025 [1] - KB-0742 has shown preliminary anti-tumor activity and a safety profile with no grade 3 or 4 neutropenia in over 100 patients [2] Company Overview - Kronos Bio, Inc. is focused on developing small molecule therapeutics that target deregulated transcription, a common feature in cancer and other diseases [3][4] - The company utilizes a proprietary discovery engine to identify druggable cofactors within complex transcription factor regulatory networks [3] - KB-0742 specifically targets CDK9 to address MYC deregulation in solid tumors, while another candidate, KB-9558, targets p300 for treating multiple myeloma [3][5] Clinical Insights - The pharmacokinetic modeling for the 80mg dosing schedule indicates a 1.8-fold increase in AUC over seven days compared to the previous 60mg schedule [2] - In the U.S., there are approximately 22,000 new ovarian cancer cases annually, with a five-year survival rate below 50%, highlighting the significant unmet medical need in this patient population [2] - KB-0742 has provided prolonged stable disease for over 300 days in at least one patient, indicating potential benefits for those with limited treatment options after platinum therapy [3]